Jazz Pharmaceuticals JAZZ Derivative Liabilities - Not Offset Policy Election Deduction
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's derivative liabilities - not offset policy election deduction.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's derivative liabilities - not offset policy election deduction?
- Jazz Pharmaceuticals (JAZZ) reported derivative liabilities - not offset policy election deduction of $8.5M in Q1 2026.
- How has Jazz Pharmaceuticals's derivative liabilities - not offset policy election deduction changed year-over-year?
- Jazz Pharmaceuticals's derivative liabilities - not offset policy election deduction increased by 5114.7% year-over-year, from $163K to $8.5M.
- What is the long-term trend for Jazz Pharmaceuticals's derivative liabilities - not offset policy election deduction?
- Over 4 years (2020 to 2025), Jazz Pharmaceuticals's derivative liabilities - not offset policy election deduction has grown at a 3.7% compound annual growth rate (CAGR), from $3.63M to $4.2M.